UnitedHealth shares traded flat Monday as investors stayed cautious ahead of the company’s second-quarter earnings report due Tuesday, according to Benzinga. Analysts expect earnings per share of $4.63. Last quarter, UnitedHealth missed estimates by nine cents, contributing to a year-over-year stock decline of over 50%. Investor focus remains on whether management will issue guidance signaling a recovery in the second half of 2025. Concerns around reimbursement trends and regulation persist, despite a 9.8% revenue growth rate as of March 31 and continued leadership in private insurance. JPMorgan maintains an “Outperform” rating with a $373.50 price target, implying nearly 33% upside. Skepticism lingers after the first-quarter earnings miss triggered a 22% share price drop. UnitedHealth shares were down 0.16% at $281.55 at the time of writing, according to Benzinga Pro.
